©The Author(s) 2026.
World J Gastroenterol. Feb 14, 2026; 32(6): 115556
Published online Feb 14, 2026. doi: 10.3748/wjg.v32.i6.115556
Published online Feb 14, 2026. doi: 10.3748/wjg.v32.i6.115556
Table 3 Adverse treatment reaction, n (%)
| Before PSM | After PSM | |||||||
| HIPEC + AC group | AC group | χ2 | P value | HIPEC + AC group | AC group | χ2 | P value | |
| Myelosuppression | 0.912 | 0.339 | 1.006 | 0.316 | ||||
| Yes | 27 (28.13) | 44 (34.11) | 24 (30.00) | 30 (37.50) | ||||
| No | 69 (71.88) | 85 (65.89) | 56 (70.00) | 50 (62.50) | ||||
| Liver function abnormalities | 0.047 | 0.829 | 0.000 | 1.000 | ||||
| Yes | 11 (11.46) | 16 (12.40) | 10 (12.50) | 10 (12.50) | ||||
| No | 85 (88.54) | 113 (87.60) | 70 (87.50) | 70 (87.50) | ||||
- Citation: Lian WL, Cai LS, Lian MQ, Lian MJ, Sun YQ, Lv CB, Huang GP, Huang RJ, Zhang YB, Zeng WM, Xu QH, Zhu QJ, Chen QX. Efficacy and safety of sequential hyperthermic intraperitoneal chemotherapy following surgery for pathological T staging 4 gastric cancer. World J Gastroenterol 2026; 32(6): 115556
- URL: https://www.wjgnet.com/1007-9327/full/v32/i6/115556.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i6.115556